Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Ambrosini, Valentina; Kunikowska, Jolanta; Baudin, Eric; Bodei, Lisa; Bouvier, Catherine; Capdevila, Jaume; Cremonesi, Marta; de Herder, Wouter; Dromain, Clarisse; Falconi, Massimo; Fani, Melpomeni; Fanti, Stefano; Hicks, Rodney; Kabasakal, Levent; Kaltsas, Gregory; Lewington, Val; Minozzi, Silvia; Cinquini, Michela; Oberg, Kjell; Oyen, Wim; O'Toole, Dermot; Pavel, Marianne; Ruszniewski, Philippe; Scarpa, Aldo; Strosberg, Jonathan; Sundin, Anders; Taieb, David; Virgolini, Irene; Wild, Damian; Herrmann, Ken; Yao, James

doi:10.1016/j.ejca.2021.01.008

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Atıf İçin Kopyala

Ambrosini V., Kunikowska J., Baudin E., Bodei L., Bouvier C., Capdevila J., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.146, ss.56-73, 2021 (SCI-Expanded)

Yayın Türü: Makale / Derleme
Cilt numarası: 146
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.ejca.2021.01.008
Dergi Adı: EUROPEAN JOURNAL OF CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.56-73
İstanbul Üniversitesi Adresli: Evet

Özet

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).